Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.54 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.51 |
| ▸ | MDM4 | O15151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13154988 | 0.96 | PTPN1 (0.51) | PTPN1FDFT1MDM4TP53 | |
| SCHEMBL15505343 | 0.92 | FDFT1 (0.48) | PTPN1FDFT1MDM4TP53 | |
| SCHEMBL29385108 | 0.90 | PTPN1 (0.56) | PTPN1 | |
| SCHEMBL29700028 | 0.90 | PTPN1 (0.56) | PTPN1MDM4TP53 | |
| SCHEMBL30153671 | 0.90 | PTPN1 (0.56) | PTPN1MDM4TP53 | |
| SCHEMBL29990051 | 0.90 | PTPN1 (0.56) | PTPN1MDM4TP53 | |
| SCHEMBL30845899 | 0.89 | CASP3 (0.53) | PTPN1FDFT1MDM4TP53 | |
| SCHEMBL29785164 | 0.89 | FDFT1 (0.59) | PTPN1FDFT1MDM4TP53 | |
| SCHEMBL4600701 | 0.89 | FDFT1 (0.57) | FDFT1MDM4TP53 | |
| SCHEMBL800035 | 0.89 | FDFT1 (0.57) | FDFT1MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112759632-B | Preparation method of Sylvestin | 昆明龙津药业股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| US-20220047698-A1 | SYNTHETIC INNATE IMMUNE RECEPTOR LIGANDS AND USES THEREOF | ALBERTA RES CHEMICALS INC (CA) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047698-A1 | SYNTHETIC INNATE IMMUNE RECEPTOR LIGANDS AND USES THEREOF | TLR3, TLR4, TLR9 | PTPN1 234/4885FDFT1 1844/4885MDM4 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.